forward
after-mkt-clos tuesday galapago announc posit updat
flamingo studi evalu cftr corrector
monotherapi placebo homozyg cf patient
think data support clearer signal efficaci
potenti clearli evid previous report
albatross combo studi ivacaftor await result
pelican studi expect provid first true
competit potenti glpg cf platform rel vertex
buy pt reiter buy rate current
minim valu cf incorpor model
earli result flamingo support role
tripl combo studi data point provid think
reduct sweat chlorid level compel lack
signific increas percent predict level report
consist corrector use monotherapi
also report well toler studi discontinu
although patient onset two pulmonari exacerb
follow period also view recruit
patient vertex recruit phase studi posit
pelican data allow compar
vertex pipelin pelican test cftr corrector
triplet compon orkambi lumacaftor ivacaftor
homozyg patient studi provid insight
addit benefit set magnitud well-
establish baselin improv orkambi although
provid direct compar vertex current triplet effort use
tezacaftor backbon corrector instead lumacaftor
first tripl studi data expect mid dose first
cf patient cftr potenti combin
cftr corrector expect howev
think dose titrat may problemat given
possibl accumul issu daili dose glpg novel
potenti seem current hope proprietari
potenti dose healthi volunt alreadi begun
valuat valu glpg ev/ sale
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
forward
pelican data allow compar
vertex pipelin pelican test cftr corrector
triplet compon orkambi lumacaftor ivacaftor
homozyg patient studi provid insight
addit benefit set magnitud well-
establish baselin improv orkambi although
provid direct compar vertex current triplet effort use
tezacaftor backbon corrector instead lumacaftor first cf
patient dose result expect like
figur pelican studi design orkambi-tr patient
dual combin studi ramp dual studi
cf patient along
schedul begin presum studi
focus homozyg residu function popul
healthi volunt studi well toler
one temporari discontinu elev liver enzym one
discontinu due maculopapular rash
figur dual combin healthi volunt
first tripl studi data expect mid dose first
cf patient cftr potenti combin
cftr corrector expect howev
think dose titrat may problemat given
possibl accumul issu daili dose glpg novel
potenti seem current hope proprietari
potenti first healthi volunt dose
top-line result expect present futur medic
galapago inc incom statement good margin develop administr market market profit margin valu re-measur share sub financi financi tax share share ep growth yoynon-gaap adjustmentsgaap epsshar
btig cover compani mention report
appendix analyst certif import disclosur
